Literature DB >> 25667108

Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer.

L M Wong1, D E Neal2, A Finelli3, S Davis4, C Bonner4, J Kapoor4, J Trachtenberg3, B Thomas2, C M Hovens4, A J Costello4, N M Corcoran4.   

Abstract

BACKGROUND: In an era of personalized medicine, individualized risk assessment using easily available tools on the internet and the literature are appealing. However, uninformed use by clinicians and the public raises potential problems. Herein, we assess the performance of published models to predict insignificant prostate cancer (PCa), using a multi-national low-risk population that may be considered for active surveillance (AS) based on contemporary practice.
METHODS: Data on men suitable for AS but undergoing upfront radical prostatectomy were pooled from three international academic institutions in Cambridge (UK), Toronto (Canada) and Melbourne (Australia). Four predictive models identified from literature review were assessed for their ability to predict the presence of four definitions of insignificant PCa. Evaluation was performed using area under the curve (AUC) of receiver operating characteristic curves and Brier scores for discrimination, calibration curves and decision curve analysis.
RESULTS: A cohort of 460 men meeting the inclusion criteria of all four nomograms was identified. The highest AUCs calculated for any of the four models ranged from 0.618 to 0.664, suggesting weak positive discrimination at best. Models had best discriminative ability for a definition of insignificant disease characterized by organ-confined Gleason score ⩽6 with a total volume ⩽0.5 ml or 1.3 ml. Calibration plots showed moderate range of predictive ability for the Kattan model though this model did not perform well at decision curve analysis.
CONCLUSIONS: External assessment of models predicting insignificant PCa showed moderate performance at best. Uninformed interpretation may cause undue anxiety or false reassurance and they should be used with caution.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25667108     DOI: 10.1038/pcan.2015.1

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  29 in total

1.  General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations.

Authors:  Lih-Ming Wong; Richard Johnston; Naomi Sharma; Nimish C Shah; Anne Y Warren; David E Neal
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

Review 2.  Everything you always wanted to know about evaluating prediction models (but were too afraid to ask).

Authors:  Andrew J Vickers; Angel M Cronin
Journal:  Urology       Date:  2010-10-27       Impact factor: 2.649

3.  A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance.

Authors:  Beverley A O'Brien; Ronald J Cohen; Andrew Ryan; Shomik Sengupta; John Mills
Journal:  J Urol       Date:  2011-09-25       Impact factor: 7.450

4.  Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.

Authors:  Niall M Corcoran; Matthew K H Hong; Rowan G Casey; Antonio Hurtado-Coll; Justin Peters; Laurence Harewood; S Larry Goldenberg; Chris M Hovens; Anthony J Costello; Martin E Gleave
Journal:  BJU Int       Date:  2011-03-28       Impact factor: 5.588

5.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

6.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

7.  Decision curve analysis: a novel method for evaluating prediction models.

Authors:  Andrew J Vickers; Elena B Elkin
Journal:  Med Decis Making       Date:  2006 Nov-Dec       Impact factor: 2.583

8.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

9.  Comparative validation of nomograms predicting clinically insignificant prostate cancer.

Authors:  Viacheslav Iremashvili; Mark S Soloway; Lisét Pelaez; Daniel L Rosenberg; Murugesan Manoharan
Journal:  Urology       Date:  2013-04-03       Impact factor: 2.649

10.  A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.

Authors:  Hiroyuki Nakanishi; Xuemei Wang; Atsushi Ochiai; Kiril Trpkov; Asli Yilmaz; J Bryan Donnelly; John W Davis; Patricia Troncoso; R Joseph Babaian
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860

View more
  4 in total

1.  Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.

Authors:  G I Russo; T Castelli; V Favilla; G Reale; D Urzì; S Privitera; E Fragalà; S Cimino; G Morgia
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-06-02       Impact factor: 5.554

2.  Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning.

Authors:  Michael S Manak; Jonathan S Varsanik; Brad J Hogan; Matt J Whitfield; Wendell R Su; Nikhil Joshi; Nicolai Steinke; Andrew Min; Delaney Berger; Robert J Saphirstein; Gauri Dixit; Thiagarajan Meyyappan; Hui-May Chu; Kevin B Knopf; David M Albala; Grannum R Sant; Ashok C Chander
Journal:  Nat Biomed Eng       Date:  2018-09-17       Impact factor: 25.671

3.  Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

4.  [Active surveillance for low-risk prostate cancer].

Authors:  Annika Herlemann; Christian G Stief
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.